Skip to main content

Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)

Dr. Lukacova’s outstanding contributions to pharmaceutical research and innovation to be recognized with seven others at AAPS PharmSci 360

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, is proud to announce that Dr. Viera Lukacova, Chief Science Officer of the SLP Division, has been elevated to the status of Fellow within the American Association of Pharmaceutical Scientists (AAPS) and will be formally inducted at the annual PharmSci 360 meeting on October 22, 2023.

“Viera stands out as an eminent figure whose profound contributions have significantly shaped the landscape of physiologically based pharmacokinetics (PBPK) modeling,” said John DiBella, President of the SLP Division at Simulations Plus. “Her scientific insights have advanced the capabilities of software platforms like GastroPlus®, DDDPlus™, and MembranePlus™ that scientists use every day to develop safe and effective treatments for patients worldwide. A tireless advocate, her impact also extends beyond research into the realms of publication, presentation, and education. Through her visionary leadership, pioneering research, and relentless dedication, she has elevated PBPK modeling to unprecedented heights, and we cannot wait to celebrate the well-deserved status she has achieved within AAPS at October’s meeting.”

“The Class of 2023 AAPS Fellows […] were selected based on well-defined criteria for outstanding scientific accomplishments, significant and sustained impact in the pharmaceutical sciences, and exceptional service to the AAPS community,” said AAPS 2023 Fellows Committee Chair Mandip Singh Sachdeva, Ph.D., FAAPS.

Joining Dr. Lukacova as 2023 AAPS Fellows are Dr. Shaukat Ali, Dr. Ben Boyd, Dr. Maria Croyle, Dr. Otilia Koo, Dr. Xiuling Lu, Dr. Wellington Pham, and Dr. Patrick Ronaldson.

To meet with Dr. Lukacova at the 2023 AAPS PharmSci 360 meeting in Orlando, Florida, and learn more about her work, we invite you to schedule a meeting and visit Simulations Plus at booth #2301 in the exhibit hall.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2022 ESG update.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.